Form 4: Thermo Fisher Scientific Executive Michel Lagarde Reports Adjustment in Performance-Based Restricted Stock Units
SEC Form 4 Filing
Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific, reports an adjustment in the number of performance-based restricted stock units received due to the company's relative total shareholder return.
Summary
- This Form 4 filing reports changes in beneficial ownership of Thermo Fisher Scientific (TMO) stock by Michel Lagarde, Executive Vice President & COO.
- The reported transactions occurred on February 28, 2025.
- The transactions involve the disposition of common stock to cover tax obligations related to the vesting of performance-based restricted stock units.
- A downward adjustment of 633 shares was made to a performance-based restricted stock unit award granted on February 23, 2022, due to the company's relative total shareholder return (TSR) over the measurement period from January 1, 2022, to December 31, 2024.
- The third tranche of the award was adjusted downward by 30% as a result of the company's relative TSR.
- Following the reported transactions, Lagarde directly owns 24,441.112 shares of Thermo Fisher Scientific common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While the adjustment to the stock units is a negative, it's a standard part of performance-based compensation and doesn't necessarily indicate a fundamental problem with the company.
Negatives
- The downward adjustment of 633 shares in the performance-based restricted stock unit award indicates that Thermo Fisher Scientific's relative total shareholder return (TSR) did not meet the initial expectations for the period from January 1, 2022, to December 31, 2024.
Risks
- Fluctuations in Thermo Fisher Scientific's total shareholder return (TSR) can impact the value of performance-based equity awards for executives.
- Unfavorable TSR performance could potentially affect executive compensation and morale.
Industry Context
Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. The adjustment to the performance-based restricted stock units reflects the direct link between executive compensation and company performance, a common practice in the industry to align management interests with shareholder value.
Comparison to Industry Standards
- Performance-based equity compensation is a common practice among large, publicly traded companies like Thermo Fisher Scientific.
- Companies such as Danaher, Agilent Technologies, and PerkinElmer also utilize similar compensation structures to incentivize executives based on metrics like TSR.
- The specific TSR targets and vesting schedules vary from company to company, but the underlying principle of aligning executive compensation with shareholder returns remains consistent.
Stakeholder Impact
- Shareholders may view the adjustment in performance-based stock units as an indication of the company's TSR performance during the specified period.
- Employees may be impacted by the company's TSR performance, as it can affect the value of their equity-based compensation.
Key Dates
| Date | Description |
|---|---|
| 2022/01/01 | Start of measurement period for relative total shareholder return (TSR). |
| 2022/02/23 | Date of grant for the performance-based restricted stock unit award. |
| 2023/02/22 | Reporting person reported the acquisition of the performance-based restricted stock unit award. |
| 2023/02/28 | One-third of the shares vested. |
| 2024/02/28 | One-third of the shares vested. |
| 2024/12/31 | End of measurement period for relative total shareholder return (TSR). |
| 2025/02/28 | Date of transaction and vesting of the remaining one-third of the shares, subject to adjustment. |
| 2025/03/04 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.